Literature DB >> 17062713

Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.

Roger N Pearse1.   

Abstract

Bone disease in patients with multiple myeloma (MM) is characterized by uncoupled bone remodeling, evident as enhanced osteolytic resorption and decreased rather than increased bone formation. MM-triggered osteolysis follows deregulation of the receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin cytokine axis. Inhibition of bone formation may result from the ability of MM to inhibit the function of Wnts, secreted glycoproteins critical to osteoblast development. Recent studies show how these processes may be linked.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17062713     DOI： 10.1158/1078-0432.CCR-06-0648

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  6 in total

1.  NF-κB Has a Direct Role in Inhibiting Bmp- and Wnt-Induced Matrix Protein Expression.

Authors:  Rohinton S Tarapore; Jason Lim; Chen Tian; Sandra Pacios; Wenmei Xiao; Daniel Reid; Hancheng Guan; Marcelo Mattos; Bo Yu; Cun-Yu Wang; Dana T Graves
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

2.  Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.

Authors:  Stavroula Baritaki; Sara Huerta-Yepez; Ma da Lourdas Cabrava-Haimandez; Marialuisa Sensi; Silvana Canevari; Massimo Libra; Manuel Penichet; Haiming Chen; James R Berenson; Benjamin Bonavida
Journal:  For Immunopathol Dis Therap       Date:  2011-04-01

3.  Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen.

Authors:  Yugal Behl; Michelle Siqueira; Javier Ortiz; Jingchao Li; Tesfahun Desta; Dan Faibish; Dana T Graves
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.

Authors:  K Sfiridaki; C A Pappa; G Tsirakis; P Kanellou; M Kaparou; M Stratinaki; G Sakellaris; G Kontakis; M G Alexandrakis
Journal:  Mediators Inflamm       Date:  2011-09-18       Impact factor: 4.711

Review 5.  Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma.

Authors:  Anna Shvartsur; Kevin B Givechian; Hermes Garban; Benjamin Bonavida
Journal:  J Exp Clin Cancer Res       Date:  2017-05-05

6.  Inhibition of osteoblastic bone formation by nuclear factor-kappaB.

Authors:  Jia Chang; Zhuo Wang; Eric Tang; Zhipeng Fan; Laurie McCauley; Renny Franceschi; Kunliang Guan; Paul H Krebsbach; Cun-Yu Wang
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.